Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
Sibbing D, Gross L, Trenk D, Jacobshagen C, Geisler T, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Parma R, Felix SB, Neumann FJ, Hausleiter J, Baylacher M, Koltowski L, Mehilli J, Huber K, Huczek Z, Aradi D, Massberg S; TROPICAL-ACS Investigators. Sibbing D, et al. Among authors: huber k. Eur Heart J. 2018 Aug 1;39(29):2749-2758. doi: 10.1093/eurheartj/ehy332. Eur Heart J. 2018. PMID: 29912422 Clinical Trial.
Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.
Gyöngyösi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hödl R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K; ReoPro-BRIDGING Study Group. Gyöngyösi M, et al. Among authors: huber k. Eur Heart J. 2004 Dec;25(23):2125-33. doi: 10.1016/j.ehj.2004.09.018. Eur Heart J. 2004. PMID: 15571828 Clinical Trial.
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.
Szük T, Gyöngyösi M, Homorodi N, Kristóf E, Király C, Edes IF, Facskó A, Pavo N, Sodeck G, Strehblow C, Farhan S, Maurer G, Glogar D, Domanovits H, Huber K, Edes I. Szük T, et al. Among authors: huber k. Am Heart J. 2007 Feb;153(2):289-95. doi: 10.1016/j.ahj.2006.10.030. Am Heart J. 2007. PMID: 17239691 Clinical Trial.
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Murphy SA, et al. Among authors: huber k. Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5. Eur Heart J. 2008. PMID: 18682445 Free PMC article. Clinical Trial.
Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry.
Suessenbacher A, Doerler J, Alber H, Aichinger J, Altenberger J, Benzer W, Christ G, Globits S, Huber K, Karnik R, Norman G, Siostrzonek P, Zenker G, Pachinger O, Weidinger F. Suessenbacher A, et al. Among authors: huber k. EuroIntervention. 2008 Aug;4(2):271-6. doi: 10.4244/eijv4i2a47. EuroIntervention. 2008. PMID: 19110794
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Kuliczkowski W, et al. Among authors: huber k. Eur Heart J. 2009 Feb;30(4):426-35. doi: 10.1093/eurheartj/ehn562. Epub 2009 Jan 27. Eur Heart J. 2009. PMID: 19174428 Review.
Prognostic value of apoptosis markers in advanced heart failure patients.
Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, Hülsmann M, Berger R, Mörtl D, Huber K, Wojta J, Pacher R. Niessner A, et al. Among authors: huber k. Eur Heart J. 2009 Apr;30(7):789-96. doi: 10.1093/eurheartj/ehp004. Epub 2009 Feb 4. Eur Heart J. 2009. PMID: 19196721
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schömig A; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Mehilli J, et al. Among authors: huber k. Circulation. 2009 Apr 14;119(14):1933-40. doi: 10.1161/CIRCULATIONAHA.108.818617. Epub 2009 Mar 30. Circulation. 2009. PMID: 19332467 Clinical Trial.
2,101 results